Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)*

Organization & Developments: Ironwood

Parents

2011: Ironwood, Forest Seek FDA Approval (2011)
2020: Ironwood Is Worth A Look As A Speculative Investment
2020: Two years after Alex Denner activist attack, Ironwood plots mass layoffs as last clinical program goes up in smoke – Endpoints News
2022: Ironwood Pharmaceuticals: Rinse, Wash And Repeat_seekingalpha.com
2023: Ironwood Pharmaceuticals: The Right Play Now
2026: Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
Its primary compound Linzess which is marketed and distributed by Allergan.
Submitted an application to the FDA for approval of their drug linaclotide, a treatment for irritable bowel syndrome with constipation and chronic constipation.(2011)